This site is intended for healthcare professionals

FDA issues Complete Response Letter for tralokinumab for the treatment of adults with moderate-to-severe atopic dermatitis.- Leo Pharma.

Read time: 1 mins
Last updated:4th May 2021
Published:4th May 2021
Condition: Atopic Dermatitis (Eczema)
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest